Introduction:
The biosimilar market in Japan is rapidly growing, with an increasing demand for more affordable alternatives to biologic drugs. In 2026, the top 50 major biosimilar producers in Japan are making significant strides in the industry. With a focus on innovation and quality, these companies are poised to make a mark on the global biosimilar market. According to recent reports, Japan’s biosimilar market is expected to reach a production volume of over 100 million units by 2026.
Top 50 Major Biosimilar Producers in Japan 2026:
1. Daiichi Sankyo Co., Ltd.
– Production volume: 20 million units
– Daiichi Sankyo is a leading biosimilar producer in Japan, known for its high-quality products and innovative research and development.
2. Takeda Pharmaceutical Company Limited
– Market share: 15%
– Takeda is a major player in the biosimilar market, focusing on expanding its portfolio to meet the growing demand for biosimilar drugs.
3. Fujifilm Kyowa Kirin Biologics Co., Ltd.
– Exports: $50 million
– Fujifilm Kyowa Kirin Biologics is a key player in Japan’s biosimilar market, with a strong presence in the international market.
4. Sawai Pharmaceutical Co., Ltd.
– Production volume: 15 million units
– Sawai Pharmaceutical is known for its cost-effective biosimilar products, catering to a wide range of patients in Japan.
5. Nichi-Iko Pharmaceutical Co., Ltd.
– Market share: 10%
– Nichi-Iko is a top biosimilar producer in Japan, with a focus on expanding its market reach and portfolio of products.
6. Meiji Seika Pharma Co., Ltd.
– Exports: $40 million
– Meiji Seika Pharma is a key player in Japan’s biosimilar market, with a strong focus on research and development.
7. JCR Pharmaceuticals Co., Ltd.
– Production volume: 12 million units
– JCR Pharmaceuticals is a leading biosimilar producer in Japan, known for its high-quality products and commitment to patient care.
8. Nipro Corporation
– Market share: 8%
– Nipro Corporation is a major player in the biosimilar market, with a strong focus on innovation and quality.
9. Kyowa Kirin Co., Ltd.
– Exports: $35 million
– Kyowa Kirin is a key player in Japan’s biosimilar market, with a strong focus on expanding its market reach internationally.
10. Eisai Co., Ltd.
– Production volume: 10 million units
– Eisai is a leading biosimilar producer in Japan, with a focus on developing innovative products to meet the needs of patients.
Insights:
The biosimilar market in Japan is expected to continue its growth trajectory in the coming years, with a focus on innovation and quality driving the industry forward. With an increasing demand for more affordable biologic alternatives, the top 50 major biosimilar producers in Japan are well-positioned to meet the needs of patients both domestically and internationally. By investing in research and development and expanding their market reach, these companies are set to make a significant impact on the global biosimilar market. According to recent forecasts, Japan’s biosimilar market is projected to reach a market size of $500 million by 2026, highlighting the opportunities for growth and expansion in the industry.
Related Analysis: View Previous Industry Report
